123 related articles for article (PubMed ID: 36483568)
1. Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions.
Schriek AI; van Haaren MM; Poniman M; Dekkers G; Bentlage AEH; Grobben M; Vidarsson G; Sanders RW; Verrips T; Geijtenbeek TBH; Heukers R; Kootstra NA; de Taeye SW; van Gils MJ
Front Immunol; 2022; 13():1091668. PubMed ID: 36483568
[TBL] [Abstract][Full Text] [Related]
2. Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions.
Schriek AI; van Haaren MM; Poniman M; Dekkers G; Bentlage AEH; Grobben M; Vidarsson G; Sanders RW; Verrips T; Geijtenbeek TBH; Heukers R; Kootstra NA; de Taeye SW; van Gils MJ
Front Immunol; 2022; 13():893648. PubMed ID: 35651621
[TBL] [Abstract][Full Text] [Related]
3. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
[TBL] [Abstract][Full Text] [Related]
4. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo.
Wang P; Gajjar MR; Yu J; Padte NN; Gettie A; Blanchard JL; Russell-Lodrigue K; Liao LE; Perelson AS; Huang Y; Ho DD
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18002-18009. PubMed ID: 32665438
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
6. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
Front Immunol; 2021; 12():733958. PubMed ID: 34566999
[TBL] [Abstract][Full Text] [Related]
7. Nanobodies that Neutralize HIV.
Weiss RA; Verrips CT
Vaccines (Basel); 2019 Jul; 7(3):. PubMed ID: 31370301
[TBL] [Abstract][Full Text] [Related]
8. Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination.
Nduati EW; Gorman MJ; Sein Y; Hermanus T; Yuan D; Oyaro I; Muema DM; Ndung'u T; Alter G; Moore PL
AIDS; 2021 Oct; 35(12):1895-1905. PubMed ID: 34115644
[TBL] [Abstract][Full Text] [Related]
9. Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs.
Moliner-Morro A; J Sheward D; Karl V; Perez Vidakovics L; Murrell B; McInerney GM; Hanke L
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33322557
[TBL] [Abstract][Full Text] [Related]
10. Nanobody-based microfluidic human Fc assay for preclinical plasma quantification of IgG1/1.1 and IgG1-Fc-conjugates.
Skottrup PD; Døssing H; Andersen NW; Buch-Rasmussen L
J Immunol Methods; 2022 Mar; 502():113214. PubMed ID: 34998814
[TBL] [Abstract][Full Text] [Related]
11. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum: Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1.
Hioe CE; Liu X; Banin AN; Heindel DW; Klingler JR; Rao PG; Luo CC; Jiang X; Pandey S; Ordonez T; Barnette P; Totrov M; Zhu J; Na das A; Zolla-Pazner S; Upadhyay C; Shen X; Kong XP; Hessell AJ
Front Immunol; 2023; 14():1329069. PubMed ID: 38022586
[TBL] [Abstract][Full Text] [Related]
13. Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell.
Qasemi M; Behdani M; Shokrgozar MA; Molla-Kazemiha V; Mohseni-Kuchesfahani H; Habibi-Anbouhi M
Protein Expr Purif; 2016 Jul; 123():19-25. PubMed ID: 26996993
[TBL] [Abstract][Full Text] [Related]
14. Generation of Multivalent Nanobody-Based Proteins with Improved Neutralization of Long α-Neurotoxins from Elapid Snakes.
Wade J; Rimbault C; Ali H; Ledsgaard L; Rivera-de-Torre E; Abou Hachem M; Boddum K; Mirza N; Bohn MF; Sakya SA; Ruso-Julve F; Andersen JT; Laustsen AH
Bioconjug Chem; 2022 Aug; 33(8):1494-1504. PubMed ID: 35875886
[TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Inside-Out Control of Fc-Receptors.
Koenderman L
Front Immunol; 2019; 10():971. PubMed ID: 31134069
[TBL] [Abstract][Full Text] [Related]
16. Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates.
Chen W; Xiao X; Wang Y; Zhu Z; Dimitrov DS
Antiviral Res; 2010 Oct; 88(1):107-15. PubMed ID: 20709110
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.
Bournazos S; Klein F; Pietzsch J; Seaman MS; Nussenzweig MC; Ravetch JV
Cell; 2014 Sep; 158(6):1243-1253. PubMed ID: 25215485
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine-Nanobody Complex.
Desmyter A; Spinelli S; Boutton C; Saunders M; Blachetot C; de Haard H; Denecker G; Van Roy M; Cambillau C; Rommelaere H
Front Immunol; 2017; 8():884. PubMed ID: 28871249
[TBL] [Abstract][Full Text] [Related]
19. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.
van Erp EA; Luytjes W; Ferwerda G; van Kasteren PB
Front Immunol; 2019; 10():548. PubMed ID: 30967872
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum: Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.
Hrvat A; Benders S; Kimmig R; Brandau S; Mallmann-Gottschalk N
Front Immunol; 2024; 15():1420991. PubMed ID: 38742114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
